Researchers propose new risk groups for NK-AMLMay 8, 2019AMLLeukemia, Myelodysplasia, TransplantationHematology
FDA approves ivosidenib frontline for certain AML patientsMay 3, 2019AMLLeukemia, Myelodysplasia, Transplantation
Study highlights lack of data on transgender leukemia patientsApril 19, 2019AMLLeukemia, Myelodysplasia, TransplantationHematology
ALF 2019 showcases evolving treatment of AMLApril 19, 2019AMLLeukemia, Myelodysplasia, Transplantation
Gilteritinib prolonged survival in FLT3-mutated AMLApril 12, 2019AMLLeukemia, Myelodysplasia, Transplantation
Anti-CD45 conditioning looks safe, feasible in relapsed AMLMarch 13, 2019AMLLeukemia, Myelodysplasia, Transplantation
In IDH-mutated AML, first-line IDH inhibitors plus chemo may boost remissionDecember 5, 2018AMLLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
Model bests IPSS-R for predicting survival, risk for AML in myelodysplastic syndromeDecember 3, 2018AMLHematology
Beat AML trial delivers genomic results in 7 daysDecember 2, 2018AMLLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
Azacitidine-nivolumab combo 'encouraging' in AMLNovember 14, 2018AMLLeukemia, Myelodysplasia, Transplantation
Pruritus linked to wide variety of cancersSeptember 16, 2018AMLLymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, Transplantation
FDA fast-tracks CX-01 for newly diagnosed AMLSeptember 4, 2018AMLLeukemia, Myelodysplasia, Transplantation
Mutations may be detectable years before AML diagnosisJuly 10, 2018AMLLeukemia, Myelodysplasia, Transplantation
A global snapshot of leukemia incidenceMarch 13, 2018AMLLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
